Chinook is a clinical-stage biopharmaceutical company discovering, developing and commercializing precision medicines for rare, severe chronic kidney diseases.

Chronic kidney diseases are a severe and growing worldwide problem with a lack of effective treatments often leading to dialysis, transplantation, and high costs to health care systems. In the U.S. alone, kidney diseases affect an estimated 37 million people and account for over $120 billion in annual costs.

Drug development in kidney diseases is experiencing a resurgence due to greater understanding of disease biology, utilization of novel translational platforms and patient stratification tools, and emergence of accelerated regulatory pathways based on surrogate endpoints. These dynamics have converged to create attractive opportunities for the development of precision therapies.

At Chinook, we are focused on rare, severe chronic kidney diseases with well-defined clinical pathways. Our lead clinical program, atrasentan, is an endothelin receptor antagonist that was in-licensed from AbbVie in 2019. The phase 3 ALIGN trial of atrasentan is currently enrolling patients with IgA nephropathy and the phase 2 AFFINITY trial of atrasentan is currently enrolling patients with proteinuric glomerular diseases. BION-1301, an investigational anti-APRIL monoclonal antibody, is being evaluated in a phase 1b trial for IgA nephropathy. We are also advancing CHK-336 for the treatment of primary hyperoxaluria towards a planned IND submission in late 2021/early 2022. In addition, we are conducting research programs in other rare, severe chronic kidney diseases. We seek to build our pipeline by leveraging insights in single cell RNA sequencing of patient kidney samples, human-derived organoids and new translational models in order to discover and develop therapeutics with mechanisms of action targeted against key kidney disease pathways.

Our Purpose & Values

We discover and develop precision therapies to preserve kidney function and make dialysis and transplant unnecessary for people living with kidney disease.

 

Chinook Values graphic

Leadership

Eric Dobmeier photo

Eric Dobmeier
President and Chief Executive Officer

Eric Bjerkholt photo

Eric Bjerkholt
Chief Financial Officer

Tom Frohlich photo

Tom Frohlich
Chief Business Officer

Alan Glicklich photo

Alan Glicklich, MD
Chief Medical Officer

Delphine Imbert photo

Delphine Imbert, PhD
SENIOR VICE PRESIDENT, CMC AND TECHNICAL OPERATIONS

Jodi Jamieson photo

Jodi Jamieson
VP, Human Resources

Andrew King photo

Andrew King, DVM, PhD
Head of Renal Discovery and Translational Medicine

Renata Oballa photo

Renata Oballa, PhD
VP, Research Operations and Vancouver Site Head

Kirk Shumacher photo

Kirk Schumacher, JD
SVP AND GENERAL COUNSEL

Board of Directors

Eric Dobmeier
President and CEO

Srini Akkaraju
Director

Jerel Davis
Lead Director

Michelle Griffin
Director

Ross Haghighat
Director

Dolca Thomas
Director